نتایج جستجو برای: tenecteplase
تعداد نتایج: 297 فیلتر نتایج به سال:
Over the past 20 years, clinical research has focused on the development of reperfusion therapies for acute ischemic stroke (AIS), which include the use of systemic intravenous thrombolytics (alteplase, desmoteplase, or tenecteplase), the augmentation of systemic intravenous recanalization with ultrasound, the bridging of intravenous with intra-arterial thrombolysis, the use of multi-modal appr...
Alteplase, tissue type plasminogen activator,t-PA has been the gold standard for fibrinolytic therapy in acute ischaemic stroke, approved for use by FDA within 3 hours of symptom onset. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, with prolonged plasma half life and higher fibrin selectivity, has emerged as a promising alternative intravenous alteplase. This artic...
A common complication of prosthetic heart valves is thrombosis. Although the incidence of prosthetic valve thrombosis (PVT) in the tricuspid position is high, there are not enough data on the management of it, in contrast to left-sided PVT. Here, we describe three cases of tricuspid PVT with three different management approaches: thrombolytic therapy; close observation with oral anticoagulants;...
Background and hypothesis Intravenous thrombolysis with alteplase remains standard care prior to thrombectomy for eligible patients within 4.5 h of ischemic stroke onset. However, alteplase only succeeds in reperfusing large vessel arterial occlusion prior to thrombectomy in a minority of patients. We hypothesized that tenecteplase is non-inferior to alteplase in achieving reperfusion at initia...
The advent of tissue plasminogen activators (tPA) has proven to be a game changer for treatment acute ischemic stroke. Despite the available options these thrombolytics on U.S. market, stroke centers have historically been limited singular agent—alteplase—because it is only tPA approved by FDA However, given emerging evidence from study conducted Warach and colleagues (see October 2020 issue St...
Thrombolysis is the gold standard of treatment for acute myocardial infarction (MI), however can be associated with haemorrhagic complications. To date, splenic rupture following thrombolysis has only been reported in those with an associated history of major trauma or splenomegaly. We report a case of a 47-year old female who developed splenic rupture following thrombolysis treatment with no h...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید